Drug Trial Radar · NCT06693895
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
750
Planned (sponsor's estimate)
Start
Nov 26, 2024
Primary completion
Nov 23, 2026
Study completion Nov 23, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 15 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have neither contracted varicella nor received a varicella vaccination.
Conditions
- Chickenpox
Interventions
Investigational varicella vaccineBiological
1 dose of investigational varicella vaccine administered subcutaneously.
Marketed varicella vaccineBiological
1 dose of marketed varicella vaccine administered subcutaneously.
Measles, mumps, and rubella vaccineBiological
1 dose of measles, mumps, and rubella vaccine co-administered subcutaneously or intramuscularly.
Hepatitis A vaccineBiological
1 dose of hepatitis A vaccine co-administered intramuscularly.
PCV (pneumococcal conjugate vaccine) 13Biological
1 dose of 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
PCV 20Biological
1 dose of 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
VaxneuvanceBiological
1 dose of 15-valent pneumococcal conjugate (Vaxneuvance) vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting each solicited administration site eventsTime frame: Day 1 (post-dose) to Day 4
- Percentage of participants reporting each solicited systemic eventTime frame: Day 1 (post-dose) to Day 15
- Percentage of participants reporting each solicited systemic event in terms of feverTime frame: Day 1 (post-dose) to Day 22
- Percentage of participants reporting each solicited administration site eventsTime frame: Day 1 (post-dose) to Day 43
- Percentage of participants reporting solicited systemic eventsTime frame: Day 1 (post-dose) to Day 43
- Percentage of participants reporting unsolicited adverse events (AEs)Time frame: Day 1 (post-dose) to Day 43
- Percentage of participants reporting medically attended AEs (MAAE)Time frame: Day 1 (post-dose) to Day 181 (study end)
- Percentage of participants reporting serious adverse events (SAEs)Time frame: Day 1 (post-dose) to Day 181 (study end)
Locations
46 sites in 8 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Phoenix, Arizona · Withdrawn
GSK Investigational Site
Tucson, Arizona · Withdrawn
GSK Investigational Site
Huntington Park, California · Recruiting
GSK Investigational Site
National City, California · Recruiting
GSK Investigational Site
West Covina, California · Recruiting
GSK Investigational Site
Hialeah, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Chicago, Illinois · Recruiting
GSK Investigational Site
El Dorado, Kansas · Withdrawn
GSK Investigational Site
Lafayette, Louisiana · Recruiting
GSK Investigational Site
Mankato, Minnesota · Recruiting
GSK Investigational Site
Lincoln, Nebraska · Recruiting
GSK Investigational Site
Cincinnati, Ohio · Recruiting
GSK Investigational Site
Dallas, Texas · Recruiting
GSK Investigational Site
Dallas, Texas · Withdrawn
GSK Investigational Site
Houston, Texas · Recruiting
GSK Investigational Site
Richmond, Texas · Recruiting
GSK Investigational Site
Richmond, Texas · Recruiting
GSK Investigational Site
San Antonio, Texas · Withdrawn
GSK Investigational Site
Roy, Utah · Completed
GSK Investigational Site
Syracuse, Utah · Recruiting
GSK Investigational Site
Richmond, Virginia · Recruiting
GSK Investigational Site
Vienna, Virginia · Withdrawn
GSK Investigational Site
Burgas, Bulgaria · Withdrawn
GSK Investigational Site
Gabrovo, Bulgaria · Recruiting
GSK Investigational Site
Kyustendil, Bulgaria · Recruiting
GSK Investigational Site
Plovdiv, Bulgaria · Recruiting
GSK Investigational Site
Rousse, Bulgaria · Recruiting
GSK Investigational Site
Sevlievo, Bulgaria · Recruiting
GSK Investigational Site
Yambol, Bulgaria · Withdrawn
GSK Investigational Site
Aarhus N, Denmark · Recruiting
GSK Investigational Site
Copenhagen, Denmark · Recruiting
GSK Investigational Site
Hvidovre, Denmark · Recruiting
GSK Investigational Site
Odense C, Denmark · Recruiting
GSK Investigational Site
Tallinn, Estonia · Recruiting
GSK Investigational Site
Tallinn, Estonia · Recruiting
GSK Investigational Site
Hong Kong, Hong Kong · Recruiting
GSK Investigational Site
Shatin, Hong Kong · Recruiting
GSK Investigational Site
Kaunas, Lithuania · Recruiting
GSK Investigational Site
Kaunas, Lithuania · Recruiting
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.